<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="drug-table.xslt"?><drug name = "temsirolimus inj VIAL">
<dose><value>25</value>
<value>20</value>
<value>15</value>
</dose>
<route><value>IV</value>
</route>
<strength><value>25 mg/mL</value>
</strength>
<frequency><value>ONCE</value>
</frequency>
<instruction><value>Administer dose over 30 minutes, diluted in 250 mL 0.9% sodium chloride.</value>
<value>Administer dose over 60 minutes, diluted in 250 mL 0.9% sodium chloride.</value>
</instruction>
<volume><value>1.2 mL</value>
</volume>
<units><value>mg</value>
</units>
<Population><value>ADULT</value>
</Population>
<IndicationPRN></IndicationPRN>
<AdditionalNotes><value>Metastatic Renal Cell Carcinoma. Dose reduction levels level (-1) 20 mg, level (-2) 15 mg. Temsirolimus is contraindicated in patients with bilirubin levels greater than 1.5 times ULN.</value>
</AdditionalNotes>
<BackgroundInformation><value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=3624</value>
</BackgroundInformation>
<PRNInformation></PRNInformation>
<AHSFormularyStatus><value>Formulary with Restrictions.</value>
</AHSFormularyStatus>
<AHFSName><value>Antineoplastic Agents</value>
</AHFSName>
<HighAlert><value>YES</value>
</HighAlert>
</drug>